IL-23 Inhibitors for Psoriasis

AbstractPurpose of ReviewThe purpose of this article is to review current understanding of the role of IL-23 in psoriasis and the available results to date on clinical trials establishing the efficacy and safety of IL-23 inhibitors for use in adults with moderate-to-severe plaque psoriasis.Recent FindingsInterleukin-23, a cytokine involved in activation and maintenance of the T-helper 17 pathway, plays a key role in the immunopathogenesis of psoriasis. While antibodies to IL-12 and IL-23 have been approved in psoriasis treatment for several years, robust evidence on the key role of IL-23 has led to the newest class of biologics for the treatment of psoriasis specifically targeting only IL-23. Guselkumab, tildrakizumab, risankizumab, and mirikizumab are fully human (guselkumab) or humanized (tildrakizumab, risankizumab, and mirikizumab) monoclonal antibodies that bind to the unique p19 subunit of IL-23. Guselkumab was recently approved for use in psoriasis, while the three others remain under investigation in clinical trials.SummaryEarly data from clinical trials shows high efficacy and low short-term safety risks of IL-23 inhibition.
Source: Current Dermatology Reports - Category: Dermatology Source Type: research